Wegovy (Semaglutide 2.4 mg) Nausea When It Doesn't Go Away

How common is nausea on Wegovy 2.4 mg?

In the pooled safety analysis in the Wegovy prescribing information (three placebo-controlled trials, 2,116 adults on 2.4 mg weekly and 1,261 on placebo, treated for up to 68 weeks), nausea was reported by 44% versus 16%, vomiting by 24% versus 6%, and any gastrointestinal reaction by 73% versus 47% [1]. Treatment was permanently stopped for adverse reactions by 6.8% versus 3.2%, and nausea was the most common single reason among the listed reactions, at 1.8% versus 0.2% [1].

STEP 1, a 68-week trial of 1,961 adults with obesity or overweight and no diabetes, reported GI events leading to discontinuation in 4.5% of semaglutide participants versus 0.8% on placebo [2].

What the label says when a dose is not tolerated

Wegovy injection steps up every 4 weeks: 0.25 mg for weeks 1 through 4, 0.5 mg for weeks 5 through 8, 1 mg for weeks 9 through 12, 1.7 mg for weeks 13 through 16, then maintenance from week 17 at 2.4 mg (recommended) or 1.7 mg [1].

For adults, 2.4 mg once weekly is the recommended maintenance dose and 1.7 mg is another maintenance option [1]. If a dose is not tolerated during escalation, the label says to consider delaying that increase by 4 weeks [1].

Semaglutide's half-life is about a week, and the drug stays in the body for roughly 5 to 7 weeks after the last 2.4 mg injection [1].

Does nausea settle as treatment continues?

The Wegovy label does not report when nausea resolves at a given dose. In the two 72-week trials that compared Wegovy doses, nausea was reported by 39% on 7.2 mg, 35% on 2.4 mg and 13% on placebo, and treatment was stopped for adverse reactions by 5%, 5% and 2% (GI reasons 3%, 3% and 0.3%) [1].

Is there anything to take for the nausea?

We found no study testing whether an anti-nausea medicine or supplement relieves Wegovy-related nausea. What the label describes is the dose option above [1].

What the label flags alongside nausea

The label lists several gastrointestinal-related warnings.

Acute pancreatitis. The label tells prescribers to observe for signs and symptoms of acute pancreatitis, described as persistent severe abdominal pain, sometimes radiating to the back, which may or may not be accompanied by nausea or vomiting, and to discontinue Wegovy if pancreatitis is suspected [1]. Adjudicated acute pancreatitis occurred in 4 Wegovy-treated adults (0.2 cases per 100 patient-years) versus 1 on placebo [1].

Gallbladder disease. Cholelithiasis was reported by 1.6% versus 0.7% on placebo and cholecystitis by 0.6% versus 0.2% in the adult weight-management trials with the injection; the label says gallbladder studies and clinical follow-up are indicated if cholelithiasis is suspected [1].

Severe GI reactions. These occurred in 4.1% versus 0.9% on placebo in adult injection trials; Wegovy is not recommended in patients with severe gastroparesis, and the label's postmarketing reports include ileus, intestinal obstruction and severe constipation with fecal impaction [1].

Volume depletion and kidney injury. Acute kidney injury occurred in 0.4 versus 0.2 cases per 100 patient-years (7 versus 4 adults), more often in people with prior kidney impairment and during dose escalation, and often after GI fluid loss; the label says to monitor renal function in patients reporting reactions that could lead to volume depletion [1].

Do the tablets and younger patients differ?

For Wegovy 25 mg daily tablets, the label draws on a 64-week trial in which 204 adults received the tablets; the label says reaction types and frequencies were similar to the injection table, with severe GI reactions in 2% of tablet-treated adults versus 0% on placebo and discontinuation for adverse reactions in 6.9% versus 5.9% [1]. In the pediatric injection trial (133 patients on Wegovy versus 67 on placebo, ages 12 and older), nausea was reported by 42% versus 18% and vomiting by 36% versus 10% [1].